NaNotics LLC announced a research collaboration with Mayo Clinic to develop a NaNot that targets the soluble form of PD-L1, a tumor-generated immune inhibitor.
[NaNotics LLC (BusinessWire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
